180 Fenglin Road

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Liver and biliary tract cancer3 trials
• High blood pressure2 trials
• Lung cancer2 trials
• Pulmonary arterial hypertension2 trials
• Aortic stenosis1 trial
• Coronary artery disease1 trial
• Parkinson disease1 trial

Phase

• Phase 23 trials
• Phase 2/31 trial

Status

• Recruiting6 trials
• Active, not recruiting2 trials
• Completed2 trials

Lead sponsor

• Shanghai Zhongshan Hospital10 trials

Running trials

• Recruiting

  Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma

  NCT07570849· Phase 2· Shanghai Zhongshan Hospital· Source

  Contact: Jian Zhou, professor

• Recruiting

  Prospective, Multicenter, Randomized Controlled Clinical Study Evaluating the VitaFlow Liberty® Flex Transcatheter Aortic Valve Delivery System for the Treatment of Severe Aortic Stenosis Lesions

  NCT07145463· Shanghai Zhongshan Hospital· Source

  Contact: Wenzhi Pan, Dr

• Recruiting

  Evaluation of the Efficacy and Safety of Fecal Microbiota Transplantation for Constipation in Parkinson's Disease

  NCT06388863· Shanghai Zhongshan Hospital· Source

  Contact: Shengdi Wu

• Recruiting

  Carotid Atherosclerosis in Predicting Coronary Artery Disease

  NCT06253962· Shanghai Zhongshan Hospital· Source

  Contact: Danbo Lu, PhD

• Recruiting

  Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC

  NCT05987826· Phase 2· Shanghai Zhongshan Hospital· Source

  Contact: di ge

• Recruiting

  FreeFlow Percutaneous Atrial Septal Shunt for IPAH

  NCT06605794· Shanghai Zhongshan Hospital· Source

  Contact: Dandan CHEN, Dr

• Active, not recruiting

  Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma

  NCT04521153· Phase 2/3· Shanghai Zhongshan Hospital· Source

• Active, not recruiting

  PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery

  NCT04295317· Phase 2· Shanghai Zhongshan Hospital· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Aortic stenosis1 recruiting
• Coronary artery disease1 recruiting
• High blood pressure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Lung cancer1 recruiting
• Parkinson disease1 recruiting
• Pulmonary arterial hypertension1 recruiting

Closed trials

• Completed

  Non-Invasive Lung Water Monitoring in Pulmonary Hypertension

  NCT06942871· Shanghai Zhongshan Hospital· Source

• Completed

  Multimodal Model Predicts Treatment Efficacy and CIP Risk in Advanced NSCLC With Immunotherapy and Chemotherapy

  NCT07243899· Shanghai Zhongshan Hospital· Source